Copenhagen, Denmark, September 28, 2015 / B3C newswire / -- Today Nuevolution announced the appointment of MD Keith Nolop, who will support the company in a Chief Medical Officer consultancy role. Dr. Nolop has more than 25 years of drug development experience in multiple therapeutic areas, and has been the medical lead for numerous IND filings, clinical development programs and 5 marketed therapies including Zelboraf - a pioneering personalized medicine for the treatment of melanoma.
Previously, he served as CMO at Plexxikon and Kite Pharma, and he had several high-level clinical research roles at CoTherix and Schering-Plough. He received his MD training at Vanderbilt University School of Medicine, TN and is board-certified in Internal Medicine and Pulmonary Medicine.
"Keith brings a vast experience in preclinical and clinical development, and we are obviously honored to have him joining us" said, Thomas Franch, CSO of Nuevolution. "He will be working closely with the Nuevolution Discovery teams to push the Nuevolution's pipeline programs forward through IND enabling studies, regulatory filings and into clinical development."
Keith commented "I am pleased to assist Nuevolution in bringing their impressive pipeline of oral small molecules into the clinic for the treatment of cancers and inflammatory diseases. I look forward to this exciting challenge."
Nuevolution is a leading small molecule drug discovery biotech company founded in 2001, and based in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution's internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.
The company has developed its proprietary drug discovery platform Chemetics®, a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery platform for both identification and optimization of hit to candidate compounds. Chemetics® enables rapid oligonucleotide e.g. DNA encoded synthesis of up to billions of chemically diverse drug-like small molecule compounds, and the efficient screening and optimization of these, facilitating the identification of potent drug leads at unprecedented speed and scale.
Nuevolution has also entered into agreements with Merck & Co. (MSD), Lexicon Pharmaceuticals, GlaxoSmithKline, Novartis, Boehringer Ingelheim and Cancer Research Technology, where Lexicon Pharmaceuticals, GlaxoSmithKline and Novartis have entered into technology licensing agreements with Nuevolution. Nuevolution has also entered a scientific collaboration by and between Duke University, Howard Hughes Medical Institute, Lexicon Pharmaceuticals and Nuevolution.
Nuevolution is a privately owned company by key Scandinavian investors, including SEB Venture Capital, Sunstone Capital and Industrifonden.
Chief Scientific Officer
Phone: +45 7020 0987
Chemetics® is a registered trademark of Nuevolution.
Chemetics® is a patented technology of Nuevolution: EP1402024, EP19005829, EP2305808, US7727713, US8932992, EP1487978, EP2186897, US7413854, US8808984, EP1539980, EP1756277, US13/179283, EP1608748, EP2236606, US 7915201, EP1558744, EP2348124, AU2003273792, AU2011226815, CNZL200380104764.5, HK1082742, HK1149947, IN213390, IL167531, JP4895608, JP5643398, ZA2005/02624, NZ538993, SG111515, US8206901, US8722583, US13/455223, US14/099106, US7704925, EP1957644, US14/571941, US14/340123, US10/539288, US13/179283, CA2544153, CN201210222023.8, EP10184069.2, HK11107866.3, IL207672, IN178/MUMNP/2007, JP2010-226107, US13/455,223, US14/099106, US10/572,644, EP10192716.8, EP10192717.6, US12/095778, CA2832672, EP11720372.9, IN9924/DELNP/2012, US13/641,588.